One Biosciences has successfully raised €15 million in a Series A round intended to advance its clinical-grade, single‐cell tumor profiling platform. This funding will drive innovations in precision oncology by supporting enhanced diagnostic capabilities and targeted treatment solutions in the fight against cancer.
Back to Top / Thursday, July 17, 2025, 7:20 am / permalink 10278 / 1 stories in 7 months
Outlast Closes €21M VC Fund for Baltic Startups / 5 months
Paris Beats London: Startup Hub Rankings Shift / 9 months
Shellworks secures $15M Series A to scale sustainable plastic alternative Vivomer / 2 days
Mycoverse raises €2.4M to commercialize fungal-based crop protection / 4 days
Amgen acquires Oxford’s Dark Blue Therapeutics in major biotech deal / 1 month
Swedish Legaltech Startup Legora Nets $80M in Series B Funding / 9 months
Ananda Impact Ventures Secures €73M First Close for Fifth Impact Fund / 6 wks
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.